Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Nivolumab and ipilimumab combination for advanced skin cancer

Dr James Larkin - The Royal Marsden, London, UK
Nivolumab and ipilimumab combination for advanced skin cancer ( Dr James Larkin - The Royal Marsden, London, UK )
12 Apr 2017

Long-term clinical outcomes and analyses of atezolizumab for mTNBC

Prof Peter Schmid - Barts Cancer Institute, London, UK
Long-term clinical outcomes and analyses of atezolizumab for mTNBC ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
12 Apr 2017

Checkmate 067 - combined nivolumab and ipilimumab

Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Checkmate 067 - combined nivolumab and ipilimumab ( Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017

Glycemia positively associated with prostate cancer mortality in non-diabetic men

Michael Marrone - Johns Hopkins University, Baltimore, USA
Glycemia positively associated with prostate cancer mortality in non-diabetic men ( Michael Marrone - Johns Hopkins University, Baltimore, USA )
12 Apr 2017

Durable responses to avelumab in patients with Merkel cell carcinoma

Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Durable responses to avelumab in patients with Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017

IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors

Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors ( Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA )
12 Apr 2017

Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses

Prof Peter Schmid - Barts Cancer Institute, London, UK
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
11 Apr 2017

Five-year follow-up of nivolumab in NSCLC

Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Five-year follow-up of nivolumab in NSCLC ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
11 Apr 2017

Mutations in cancer predisposition genes and risk for subsequent neoplasms

Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA
Mutations in cancer predisposition genes and risk for subsequent neoplasms ( Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA )
11 Apr 2017

Final overall survival analysis of MONARCH 1

Dr Hope Rugo - UCSF Medical Center, San Francisco, USA
Final overall survival analysis of MONARCH 1 ( Dr Hope Rugo - UCSF Medical Center, San Francisco, USA )
11 Apr 2017

Redefining tamoxifen for breast cancer

Gokul Das - Roswell Park Cancer Institute, Buffalo, USA
Redefining tamoxifen for breast cancer ( Gokul Das - Roswell Park Cancer Institute, Buffalo, USA )
11 Apr 2017

Olaparib and temozolomide for relapsed small cell lung cancer

Dr Anna Farago - Massachusetts General Hospital, Boston, USA
Olaparib and temozolomide for relapsed small cell lung cancer ( Dr Anna Farago - Massachusetts General Hospital, Boston, USA )
10 Apr 2017